Key result
Discharge spironolactone in HFmrEF is linked to a ~37% reduction in all-cause death or HF rehospitalization.
Why the study?
Spironolactone improves outcomes in HFrEF, but whether its use at discharge is associated with better long-term outcomes in HFmrEF was unclear.
Does spironolactone at discharge reduce the composite of all-cause death or HF rehospitalization in patients hospitalized for HFmrEF?
Cohort (n=457)
Yes
Does spironolactone at discharge reduce the composite of all-cause death or HF rehospitalization in patients hospitalized for HFmrEF?
Effect estimate: adjusted HR 0.63 (95% CI 0.44-0.90)
Absolute Event Rate: 171.5% vs 278.8%
p-value: p=0.010
In patients hospitalized for HFmrEF, spironolactone prescription at discharge is associated with a significantly lower risk of all-cause death or HF rehospitalization.
May support spironolactone at discharge in HFmrEF; hypothesis-generating and requires randomized confirmation before practice change.
No takes yet. Share an insight, caveat, or question.
Enzan et al. (2020) conducted a cohort in Heart failure with mid-range ejection fraction (HFmrEF) (n=457). Spironolactone vs. No spironolactone was evaluated on Composite of all-cause death or HF rehospitalization (adjusted HR 0.63, 95% CI 0.44-0.90, p=0.010). Spironolactone use at discharge in HFmrEF patients was associated with a significant reduction in all-cause death or HF rehospitalization (adjusted HR 0.63; 95% CI 0.44-0.90; P=0.010).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: